Search for more clinical trials
High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
Conditions
Medulloblastoma - Brain Tumors - Neuroectodermal Tumors, Primitive
Conditions: official terms
Brain Neoplasms - Medulloblastoma - Neoplasms - Neuroectodermal Tumors - Neuroectodermal Tumors, Primitive
Conditions: Keywords
Brain PNET
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Etoposide, carboplatin, melphalan, cisplatin, thiotepa
Type: Drug
Overall Status
Recruiting
Summary
The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 10 Years
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:
- Medulloblastoma in patients less than 5 years of age
- Brain PNET in patients less than 10 years of age
- Histologically documented diagnosis
- Body weight of > 8 kg
Exclusion Criteria:
- Parents' refusal
- Medulloblastoma in patients less than 5 years of age
- Brain PNET in patients less than 10 years of age
- Histologically documented diagnosis
- Body weight of > 8 kg
Exclusion Criteria:
- Parents' refusal
Location
Institut Gustave Roussy
Villejuif, France
Status: Recruiting
Contact: Chantal Kalifa, MD - 33 1 42 11 4166 - kalifa@igr.fr
Start Date
July 2002
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Source
Gustave Roussy, Cancer Campus, Grand Paris
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page